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To the editor: 
The TREAT study, reported by Pfeffer et al (November 19 issue) (1), of patients with chronic kidney 
disease, sought to clarify the effects of Darbepoetin alfa replacement therapy on clinical outcomes, 
by examining the effect of D-alfa vs. placebo on the composite endpoints of death or cardiovascular 
event, and death or end-stage renal disease. The target hemoglobin was 13g/dl, and the median 
(IQR) Hb achieved in the intervention group was 12.5 (12-12.8) vs. 10.6 (9.9-11.3) in the comparator 
group. 
The normal Hb range is 20-30% higher in adult males compared with children and females. The 
levels achieved in TREAT were in the lower quintile of the male range, but mid-normal for females. 
We wonder, therefore, whether the significantly increased stroke risk (HR 1.92) in the intervention 
group was disproportionately exhibited by the women, who accounted for 58.5% of the intervention 
cohort.  
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